利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.025 秒)

    DRUG-ELUTING GRAFT
    21.
    发明申请
    DRUG-ELUTING GRAFT 有权
    药物涂抹片

    公开(公告)号：US20080319425A1

    公开(公告)日：2008-12-25

    申请号：US11765915

    申请日：2007-06-20

    申请人： Stephen R. Hanson

    发明人： Stephen R. Hanson

    IPC分类号： A61M5/14

    CPC分类号： A61M1/3655 ,  A61F2/064 ,  A61F2250/0068

    摘要： Embodiments of the present invention provide a device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first element capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. In embodiments, the first element may be fully or partially microporous or a separate intermediate microporous membrane may be provided. Also provided are methods of mixing or moving a drug within a reservoir using various mixing elements. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing a device in accordance with embodiments of the present invention.

    摘要翻译： 本发明的实施方案提供了一种用于将物质局部递送到哺乳动物体内的天然组织导管中的装置，其具有能够接触导管的内腔的第一元件和覆盖第一元件的第二元件，形成的储存器 在第一元件和第二元件之间，储存器的内部能够与管道流体连通，使得放置在储存器中的物质被输送到管道中。 在实施方案中，第一元素可以是完全或部分微孔的，或者可以提供单独的中间微孔膜。 还提供了使用各种混合元件在储存器内混合或移动药物的方法。 还提供了使用根据本发明的实施方案的装置将物质局部输送到哺乳动物体内的天然组织导管中的方法。

    Vascular prosthesis
    25.
    发明授权
    Vascular prosthesis 失效
    血管假体

    公开(公告)号：US4687482A

    公开(公告)日：1987-08-18

    申请号：US604996

    申请日：1984-04-27

    申请人： Stephen R. Hanson

    发明人： Stephen R. Hanson

    IPC分类号： A61F2/06 ,  A61L27/34 ,  A61L27/50 ,  A61L33/06 ,  A61F1/24

    CPC分类号： A61L27/34 ,  A61L27/507 ,  A61L33/06 ,  Y10S534/02

    摘要： A vascular prosthesis for implantation in a living mammalian body and a method for producing same are disclosed. The vascular prosthesis has a hydrophobic polymeric layer on its luminal surface defining a substantially non-thrombogenic flow surface. The polymeric material of the layer defining the flow surface exhibits a rate of platelet consumption of less than about 20.times.10.sup.8 platelets/cm.sup.2 .multidot.day.

    摘要翻译： 公开了一种植入活体哺乳动物体内的血管假体及其制造方法。 血管假体在其腔表面上具有限定基本上非血栓形成的流动表面的疏水性聚合物层。 限定流动表面的层的聚合物材料表现出小于约20×10 8血小板/ cm 2×日的血小板消耗率。

    Drug delivery cuff
    26.
    发明授权
    Drug delivery cuff 有权
    给药袖口

    公开(公告)号：US08808255B2

    公开(公告)日：2014-08-19

    申请号：US12747048

    申请日：2008-12-12

    申请人： Stephen R. Hanson

    发明人： Stephen R. Hanson

    IPC分类号： A61M31/00 ,  A61M5/142 ,  A61F2/06

    CPC分类号： A61M31/002 ,  A61F2/06 ,  A61F2/064 ,  A61F2250/0067 ,  A61M5/14276

    摘要： Embodiments provide a drug delivery cuff including a drug reservoir. In an embodiment, an integrated drug pump may be provided. A drug delivery cuff in accordance with an embodiment may be placed around any suitable vascular graft (e.g., ePTFE) or directly around any natural tissue conduit (e.g., perivascularly), at any position along the graft/conduit or overlapping a graft and conduit, either at the time of graft surgical placement or separate therefrom.

    摘要翻译： 实施例提供了包括药物储存器的药物递送袖带。 在一个实施例中，可以提供集成的药物泵。 根据实施例的药物输送袖带可以放置在任何合适的血管移植物（例如ePTFE）周围或者在任何天然组织导管周围（例如血管周围）放置在沿着移植物/管道的任何位置处或与移植物和导管重叠， 无论是在移植手术放置时还是从其分离。

    Antithrombotic thrombin variants
    28.
    发明授权
    Antithrombotic thrombin variants 有权
    抗血栓凝血酶变体

    公开(公告)号：US06706512B2

    公开(公告)日：2004-03-16

    申请号：US10165442

    申请日：2002-06-07

    申请人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

    发明人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

    IPC分类号： C12N964

    CPC分类号： C12N9/6464 ,  A61K38/00 ,  C12N9/6429 ,  C12Q1/40 ,  C12Y304/21005 ,  C12Y304/21069 ,  G01N33/86

    摘要： The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

    摘要翻译： 本发明涉及能够蛋白水解活化蛋白C但基本上不含纤维蛋白原裂解活性的凝血酶或其片段的新型抗血栓形成变体。 本发明还涉及可被切割以产生活性凝血酶变体的变体多肽。 本发明还涉及通过将本发明的抗血栓形成变体凝血酶递送至受试者的血液来抑制动物或人受试者中血栓形成的方法。 本发明还涉及使用新型变体血栓素来测定血液样品中蛋白C活化水平或患者血栓形成潜力的方法。

    Polymeric drug formulations
    29.
    发明授权
    Polymeric drug formulations 失效

    公开(公告)号：US5877224A

    公开(公告)日：1999-03-02

    申请号：US508577

    申请日：1995-07-28

    申请人： Stephen Brocchini ,  Stephen R. Hanson ,  Joachim B. Kohn

    发明人： Stephen Brocchini ,  Stephen R. Hanson ,  Joachim B. Kohn

    IPC分类号： A61K9/10 ,  A61K9/14 ,  A61K9/20 ,  A61K9/70 ,  A61K47/30 ,  A61K47/32 ,  A61K47/34

    CPC分类号： A61K9/146 ,  A61K9/2031 ,  A61K9/204 ,  A61K9/7007

    摘要： Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.